WILMINGTON, Del.--(BUSINESS WIRE)--NiKang Therapeutics Inc. (“NiKang”), a clinical stage biotech company focused on developing innovative small molecule oncology medicines to help patients with unmet ...
This study is led by Prof. Jian-Zhi Wang (Department of Pathophysiology, Tongji Medical College, Huazhong University of Science and Technology), Prof. Jie Zheng (Department of Neurobiology, School of ...
Conventional small-molecule drugs for reducing pTau include phosphatase activators of PP2A, and kinase inhibitors of GSK3β, CDK5, etc., as well as active or passive immunotherapies targeting pTau.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results